首页> 外国专利> METHOD OF DIFFERENTIATING HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS B AND AUTOIMMUNE LIVER INJURIES

METHOD OF DIFFERENTIATING HEPATIC FIBROSIS IN CHRONIC VIRAL HEPATITIS B AND AUTOIMMUNE LIVER INJURIES

机译:鉴别慢性乙型肝炎和自身免疫性肝损伤中肝纤维化的方法

摘要

FIELD: medicine.;SUBSTANCE: invention relates to medicine and is intended for differential diagnosis of hepatic fibrosis in viral hepatitis B (HBV) and autoimmune liver injuries (ALI). Blood plasma is used to determine concentration of cytokines CCL8/MCP-2, CXCL10/IP-10, IFN γ. At the first stage, the concentration of CCL8/MCP-2 is evaluated, with values of which ≥22.9 pg/ml of the patient must be attributed to the first subgroup with advantage HBV, with values 22.9 pg/ml – to the second subgroup, with advantage ALI, then evaluating CXCL10/IP-10, if its value 660.57 pg/ml for the first subgroup is diagnosed HBV, ≥660.57 pg/ml – diagnosed ALI, for the second subgroup, if CXCL10/IP-10376.4 pg/ml is diagnosed HBV, if ≥376.4, additional analysis of IFN γ is performed if IFN γ≥7.19 pg/ml is diagnosed HBV, and if 7.19 – ALI.;EFFECT: method provides higher accuracy of differential diagnosis of hepatic fibrosis.;1 cl, 1 dwg, 4 ex
机译:技术领域本发明涉及药物,并且用于鉴别诊断乙型病毒性肝炎(HBV)和自身免疫性肝损伤(ALI)中的肝纤维化。血浆用于确定细胞因子CCL8 / MCP-2,CXCL10 / IP-10,IFNγ的浓度。在第一阶段,评估CCL8 / MCP-2的浓度,其值必须≥22.9pg / ml的患者必须归因于HBV优势的第一个亚组,而值<22.9 pg / ml的归因于第二个具有优势ALI的亚组,然后评估CXCL10 / IP-10(如果第一个亚组的值<660.57 pg / ml被诊断为HBV,≥660.57pg / ml –诊断为第二亚组的ALI,如果CXCL10 / IP-10 <376.4 pg / ml被诊断为HBV,如果≥376.4,则如果IFNγ≥7.19pg / ml被诊断为HBV,并且<7.19 – ALI,则需要对IFNγ进行进一步分析。肝纤维化; 1 cl,1 dwg,4 ex

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号